A number of CCL2/CCR2 axis inhibitors, such as CCX140-B and emapticap pegol, have also been developed, and have demonstrated a degree of clinical benefit for diabetic kidney disease in humans (de Zeeuw et al. 2015; Menne et al. 2017). The gene discussed is CCL2; the disease is diabetic kidney disease.